{
    "clinical_study": {
        "@rank": "126098", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A", 
                "arm_group_type": "Experimental", 
                "description": "ABT-165 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-165"
            }, 
            {
                "arm_group_label": "Cohort B", 
                "arm_group_type": "Experimental", 
                "description": "ABT-165 plus paclitaxel"
            }, 
            {
                "arm_group_label": "Cohort C", 
                "arm_group_type": "Experimental", 
                "description": "ABT-165 plus FOLFIRI"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and\n      preliminary efficacy of ABT-165 in subjects with advanced solid tumors. The early clinical\n      development plan for ABT-165 is based on the activity demonstrated in preclinical models."
        }, 
        "brief_title": "Study of ABT-165 in Subjects With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject must have advanced solid tumor that is not amenable to surgical resection or\n             other approved therapeutic options that have demonstrated clinical benefit.\n\n          -  Subject has adequate bone marrow, renal, hepatic and coagulation function.\n\n          -  Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors\n             (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens including\n             but not limited to cancer antigen (CA-125) and prostate-specific antigen (PSA).\n\n          -  Women of childbearing potential must have a negative serum pregnancy test within 14\n             days prior to initiation of treatment. Female subject considered not of childbearing\n             potential must be documented as being surgically sterile or post-menopausal for at\n             least 1 year. Women of childbearing potential and men must agree to use adequate\n             contraception.\n\n          -  Subjects in the combination therapy cohorts must meet the above inclusion criteria\n             and be eligible to receive paclitaxel or FOLFIRI per most current prescribing\n             information, or at the discretion of the Investigator.\n\n        Exclusion Criteria:\n\n          -  Subject has received anticancer therapy including chemotherapy, radiation therapy,\n             immunotherapy, biologic, or any investigational therapy within a period of 21 days or\n             herbal therapy within 7 days prior to Cycle 1 Day 1 of ABT-165.\n\n          -  Subject has known uncontrolled metastases to the central nervous system (CNS).\n\n          -  Subject has unresolved clinically significant toxicities from prior anticancer\n             therapy, defined as any Common Terminology Criteria for Adverse Events (CTCAE) Grade\n             2 or higher.\n\n          -  Subject has history (within previous 2 years) of hypertensive crisis, congestive\n             heart failure, myocardial infarction or the left ventricular ejection fraction (LVEF)\n             less than or equal to 50%.\n\n          -  Subjects enrolled on the combination therapy phase must not meet the above exclusion\n             criteria and must be eligible to receive paclitaxel or FOLFIRI per most current\n             prescribing information, or at the discretion of the Investigator. Subjects with\n             colorectal cancer will be excluded from the combination therapy cohorts."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946074", 
            "org_study_id": "M14-006"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort A", 
                    "Cohort B", 
                    "Cohort C"
                ], 
                "description": "ABT-165 will be administered by intravenous infusion at escalating dose levels in 28-day dosing cycles on Day 1 and 15.", 
                "intervention_name": "ABT-165", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort B", 
                "description": "Paclitaxel will be administered by intravenous infusion in 28-day dosing cycles on Day 1, 8 and 15.", 
                "intervention_name": "paclitaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort C", 
                "description": "5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and 15.", 
                "intervention_name": "FOLFIRI", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "advanced solid tumor", 
            "neoplasm", 
            "cancer"
        ], 
        "lastchanged_date": "May 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }, 
                    "name": "Site Reference ID/Investigator# 105677"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105677", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }, 
                    "name": "Site Reference ID/Investigator# 105678"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105678", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Site Reference ID/Investigator# 123758"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 123758", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Site Reference ID/Investigator# 105679"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105679", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75230"
                    }, 
                    "name": "Site Reference ID/Investigator# 123757"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 123757", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors", 
        "overall_contact": {
            "email": "annchristine.thastrom@abbvie.com", 
            "last_name": "AnnChristine  Thastrom, PhD", 
            "phone": "650.454.2045"
        }, 
        "overall_contact_backup": {
            "email": "lan.wang@abbvie.com", 
            "last_name": "Lan  Wang", 
            "phone": "650.454.2024"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Louie  Naumovski, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Collect all adverse events at each visit", 
                "measure": "Number of participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 90 days after a 24-month treatment period"
            }, 
            {
                "description": "Blood pressure, heart rate, respiratory rate and body temperature", 
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after a 24-month treatment period"
            }, 
            {
                "description": "Assessment of normal/abnormal physical findings", 
                "measure": "Physical exam", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after a 24-month treatment period"
            }, 
            {
                "description": "Hematology, Chemistry, and Urinalysis", 
                "measure": "Clinical lab testing", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after a 24-month treatment period"
            }, 
            {
                "description": "Electrocardiogram (ECG), chest X-ray, echocardiogram (ECHO) or multigated acquisition (MUGA), basic natriuretic peptide (BNP) and troponin I", 
                "measure": "Cardiac assessment", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after a 24-month treatment period"
            }, 
            {
                "measure": "Maximum observed serum concentration (Cmax) of ABT-165", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days after a 24-month of treatment period"
            }, 
            {
                "measure": "The terminal elimination half life of ABT-165", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days after a 24-month treatment period"
            }, 
            {
                "description": "AUC (0-t) = Area under the serum concentration versus time curve form time zero (pre-dose) to the time of the last measurable concentration", 
                "measure": "Area under the curve (AUC) form time zero to the last measurable concentration AUC (0-t)", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days after a 24-month treatment period"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946074"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "ORR is defined as the proportion of the subjects who have a complete response (CR) or partial response (PR)", 
                "measure": "Objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 days after a 24-month treatment period"
            }, 
            {
                "description": "PFS is defined as the time from the first dose date of ABT-165 to either disease progression or death, whichever occurs first", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 days after a 24-month treatment period"
            }, 
            {
                "description": "DOR is defined as the time from the subject's initial CR or PR to the time of disease progression", 
                "measure": "Duration of overall response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 days after a 24-month treatment period"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}